Drugs / Xla1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04663139 | Nov 2020 → Jun 2021 | metabolic disease, obesity disorder | YSOPIA Bioscience | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xla1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04663139 ↗ |
| Modality | Other / unclassified | “Live Biotherapeutic Product (LBP)” NCT04663139 ↗ |
| Route | Oral | “daily oral single dose” NCT04663139 ↗ |